LOTTE Biologics Songdo Plant 1 Lands First Major Commercial Manufacturing Agreement Ahead of Launch
LOTTE Biologics Songdo Plant 1 has secured its first major commercial manufacturing agreement with a global pharmaceutical company ahead of its operational launch. The deal covers integrated drug substance and drug product manufacturing, with commercial production targeted for 2027.
Sanofi VaxRabeo Wins European Commission Approval as Next-Generation Rabies Vaccine for All Ages
Sanofi VaxRabeo has won European Commission approval for rabies PrEP and PEP in all age groups. The Vero-cell vaccine has a 60-month shelf life and showed comparable antibody levels to Verorab and Imovax Rabies.
Pfizer Starna Licensing Agreement: Pfizer Secures Exclusive In Vivo CAR-T Rights for Autoimmune Diseases in $330 Million Upfront Deal
The Pfizer Starna licensing agreement hands Pfizer exclusive rights outside Greater China to three pre-IND in vivo CAR-T autoimmune programs, backed by a $330 million upfront payment and up to $2.3 billion in milestones.
Johnson & Johnson Announces $2.2 Billion Ollin Biosciences Acquisition to Add Phase 3 Eye Antibody OLN324
Johnson & Johnson has agreed to acquire Ollin Biosciences for $2.2 billion upfront, adding the Phase 3 bispecific antibody OLN324 for wet AMD and diabetic macular edema. A separate $750 million Blackstone Life Sciences funding agreement would support Phase 3 development.
FDA Rejected Ivonescimab: Summit Therapeutics Receives Complete Response Letter for NSCLC BLA Based on HARMONi Study
The FDA rejected ivonescimab in its present form, issuing a Complete Response Letter for Summit Therapeutics’ NSCLC BLA. The agency said a PFS benefit without significant overall survival does not establish substantial evidence of effectiveness.
Novo Nordisk CagriSema REDEFINE 9 Trial Shows ~21% Average Weight Loss at Lower Doses at ObesityWeek 2026
Novo Nordisk’s phase 3 CagriSema REDEFINE 9 trial showed estimated average weight loss of 20.7% and 21.0% at 68 weeks with lower CagriSema doses, versus 2.0% with placebo. Results were presented at ObesityWeek 2026 and published in The Lancet Diabetes & Endocrinology.
Takeda ORZEYFUL Launch Brings First Orexin Agonist for Narcolepsy Type 1 to U.S. Patients
The Takeda ORZEYFUL launch makes oveporexton, an oral orexin receptor 2 agonist, available by prescription in the U.S. for adults with narcolepsy type 1, with Accredo Specialty Pharmacy handling dispensing.
Cipher Pharmaceuticals Q3 2026 Results: Epuris Sales Rise 15%, Natroba Gains 14% as Net Income Hits $10.9M
Cipher Pharmaceuticals Q3 2026 results show net revenue of $12.7 million, net income of $10.9 million, Epuris sales up 15% and Natroba up 14% sequentially, plus a $5.7 million arbitration collection.
Merck KGaA Q3 2026 Results: Pimjetmi FDA Approval and Silence Therapeutics Deal Back a Raised Full-Year Outlook
Merck KGaA Q3 2026 results show 5.1% organic sales growth to €5.6 billion, strong Process Solutions and Rare Diseases performance, the Pimjetmi FDA approval, and a raised full-year 2026 outlook.
Novartis Rhapsido CIndU Data: Remibrutinib Shows Sustained Efficacy Through Week 52 in Phase III RemIND Study
Novartis reported 52-week Phase III RemIND results for Rhapsido (remibrutinib) in chronic inducible urticaria. Response rates held through Week 52 across symptomatic dermographism, cold urticaria and cholinergic urticaria, and additional regulatory submissions are planned.





